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Abstract
The discovery of pharmacogenomic markers in colorectal cancer (CRC) could be setting-specific.
FOLFOX4 is employed in the adjuvant and metastatic setting in CRC. This prospective study is
aimed to validate in the adjuvant setting the pharmacogenomic markers of toxicity reported in the
metastatic setting (that is, GSTP1-rs947894, and -rs1138272; GSTM1-null genotype; AGXT-
rs4426527, -rs34116584 and del-74 bp), and to discover additional markers. CRC patients (n =
144) treated with adjuvant FOLFOX4 were genotyped for 57 polymorphisms in 29 genes. Grade
≥2 neurotoxicity was associated false discovery rate-adjusted q-value <0.1) with single-nucleotide
polymorphisms in ABCC1 (rs2074087: odds ratio = 0.43(0.22–0.86)), and ABCC2 (rs3740066:
2.99(1.16–7.70); rs1885301: 3.06(1.35–6.92); rs4148396: 4.69(1.60–13.74); rs717620:
14.39(1.63–127.02)). hMSH6-rs3136228 was associated with grade 3–4 neutropenia (3.23(1.38–
7.57), q-value = 0.0937). XRCC3-rs1799794 was associated with grade 3–4 non-hematological
toxicity (8.90(2.48–31.97), q-value = 0.0150). The markers previously identified in metastatic
CRC were not validated. We have identified new markers of toxicity in genes of transport and
DNA repair. If validated in other studies, they could help to identify patients at risk of toxicity.
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Validated markers have been recently identified for treatment personalization in oncology,
with drug toxicity as the outcome of interest.1,2 This appears to be a promising field for
improving the management of colorectal cancer (CRC) therapy. However, most of the data
have been generated in the metastatic setting3–6 and it is not clear whether these markers
could be applied in different clinical settings in CRC.
Oxaliplatin in combination with fluoropyrimidines (FOLFOX4 schedule) is largely used in
the treatment of CRC in both the metastatic and the adjuvant settings. However, oxaliplatin-
based chemotherapy is limited by the occurrence of severe toxicities in a considerable
number of patients.7–9 Among those side effects, peripheral neurotoxicity is one of the most
common and disabling. Increasing cumulative doses of oxaliplatin lead to a persistent
sensory peripheral neuropathy associated with functional disability in some patients.10,11
Recent investigations establish the persistence of subjective and objective deficits in
oxaliplatin-treated patients after the interruption of oxaliplatin, suggesting that sensory
neuropathy could be a long-term sequela in more sensitive patients thereby challenging the
notion of its reversibility.12 Moreover, clinical studies investigating oxaliplatin neurotoxicity
seem to indicate a synergistic neurotoxic effect with fluoropyrimidines.13
In vitro and in vivo studies on neuronal damage mechanisms14 indicate that oxaliplatin
exerts a direct pharmacological effect on the excitability of sensory neurons and muscle cells
by interfering with voltage-gated Na+ channels.15 Another suggested mechanism is the
deposition of DNA-platinum adducts in the dorsal root ganglions, inducing neuronal damage
and apoptosis,16 with the involvement of the glutathione-related detoxification system and
the DNA repair protein complex.17
Germline variants in genes encoding DNA repair enzymes, detoxification pathways and ions
channels may be responsible of the inter-subject variability in the occurrence of oxaliplatin
toxicity. Some markers of toxicity have been previously identified in metastatic CRC
patients,18,19 but they are likely to have a different impact when dealing with adjuvant
patients, especially in relation to the neurological toxicity. First, a metastatic patient could
have undergone previous treatments with drugs with neurotoxic potential. In addition, tumor
progression and its dissemination have been related to changes in the levels of inflammatory
mediators, with associated increased oxidative stress.20,21 This could make a metastatic
patient particularly sensitive to environmental stress factors like hypoxia and oxidative
stress, resulting into DNA damage upon exposure to a cytotoxic agent.22
To our knowledge, no data are available in the adjuvant setting on genetic polymorphisms as
toxicity predictors for CRC patients treated with oxaliplatin (FOLFOX4). Hence, the
primary aims of this prospective study are (1) to investigate the role of genetic
polymorphisms previously identified in the metastatic disease as predictive markers of
toxicity (mainly neurotoxicity and neutropenia) in patients treated with adjuvant FOLFOX4;
and (2) to discover associations with putative novel biomarkers.
MATERIALS AND METHODS
Patients and study design
This multi-institution study was sponsored by the CRO-National Cancer Center of Aviano,
Italy. CRC patients (n = 154) were genotyped for 57 genetic polymorphisms in 29 candidate
genes. The main endpoint was neurotoxicity during FOLFOX4 therapy in curatively-
resected patients with stage II–III CRC. Neutropenia and any non-hematological toxicity
were evaluated as secondary endpoints. The highest grade of toxicity recorded during the
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treatment for each toxicity endpoint (that is, neurotoxicity, neutropenia and any non-
hematological toxicity) was used for association with polymorphisms. The Institutional
Review Board of each participating institution approved the study protocol, and all patients
signed a written informed consent before entering the study.
Patients with histologically confirmed CRC, and radiologically confirmed absence of distant
metastases were eligible. Eligibility criteria were as follows: stage II–III CRC; age >18
years; performance status (WHO) 0–2; normal bone marrow, renal and liver function.
Patients affected by chronic inflammatory enteric diseases, evidence of neurosensory disease
or assuming neurotoxic medications were excluded from the study. All the patients were of
Caucasian ethnicity and have been enrolled in centers located in northern and Central Italy.
Eligible patients were treated with FOLFOX4 (oxaliplatin 85 mg m−2 (2 h infusion on day
1), leucovorin (100 mg m−2 as 2 h infusion on day 1), 5-fluorouracil bolus (400 mg m−2)
and 22 h infusion (600 mg m−2) on days 1 and 2 every 2 weeks) for 6 months (12 cycles).
Toxicity evaluation
Objective clinical evaluation, blood counts, hepatic and renal function tests were performed
within 48 h before each cycle. Patients were questioned about nausea and vomiting,
mucositis, diarrhea, asthenia (that is, fatigue, malaise and weakness symptoms), and appetite
at every cycle. Toxicity was evaluated according to NCI-CTC criteria version 2.0 (http://
ctep.cancer.gov/). Neurotoxicity was evaluated according to the oxaliplatin-specific scale.23
Patients undergoing at least one cycle of chemotherapy were included in this study.
Chemotherapy was delayed until recovery from hematological toxicities or in the case of
significant, persisting, non-hematological toxicity. In the event of severe (grade 3–4)
toxicity, the doses of oxaliplatin and 5-fluorouracil were reduced by 25 or 50% based on the
physician’s evaluation. Treatment was discontinued either in the event of anaphylactic
reaction, or repeated severe toxicity in spite of dose reduction, or patient refusal.
Selection of candidate polymorphisms and genotyping assay
Genomic DNA was extracted from peripheral blood using the High Pure PCR Template
Preparation Kit (Roche Diagnostics GmbH, Mannheim, Germany). Positive controls were
included in the analyses (that is, for each polymorphism, three DNA samples for each
genotype, determined by an alternative genotyping procedure, were used as reference).
Genotyping was performed blinded to the clinical data.
Two different criteria were used for the selection of candidate genes for the
pharmacogenomic analysis: (1) gene variants included in previous pharmacogenomic
association studies of FOLFOX in metastatic CRC.18,19,24–27 (2) Variants in genes in
cellular pathways known to be involved in the pharmacokinetics and pharmacodynamics of
oxaliplatin (www.pharmgkb.org). Genes, variants, pathways and assays are listed in
Supplementary Table 1.
For pyrosequencing we used PSQ96MA (Biotage, Uppsala, Sweden). PCR amplifications
were performed in an Eppendorf Mastercycler gradient, with TaqGold DNA Polymerase
(AB Applied Biosystems, Warrington, UK). Detailed Pyrosequencing genotyping protocols
are available upon request. Predesigned or custom Taq Man single-nucleotide polymorphism
(SNP) genotyping assays were used for the allelic discrimination reactions. Predesigned Taq
Man Copy Number assays were used on ABI 7900HT (AB Applied Biosystems, Foster City,
CA, USA) for the analysis of gene deletion polymorphisms. All the commercial Taq Man
assays were purchased from Applied Biosystems (www.appliedbiosystems.com). Analyses
with Taq Man assays were performed with the Applera Taq Man Universal Master mix on
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ABI 7900HT (AB Applied Biosystems) according to the manufacturer instructions.
Automated fragment analysis was performed on ABI Prism 3130 (Applied Biosystems),
with Gene Scan software (Applied Biosystems). Detailed fragment analysis and gel
electrophoresis genotyping protocols are available upon request. AGXT polymorphisms were
analyzed as previously reported.25
Statistical analysis
The study was prospectively designed to test the association between genetic
polymorphisms and oxaliplatin neurological toxicity (grade ≥2), as the primary endpoint.
Severe neutropenia and any severe non-hematological toxicity were evaluated as secondary
endpoints. For each polymorphism, deviation from Hardy–Weinberg equilibrium was tested
by Fisher’s exact test and no deviation was found (P>0.05). Odds ratio and 95% confidence
interval were estimated by unconditional logistic regression. We investigated three genetic
models (that is, dominant, recessive and additive) for the association, and the most
statistically significant by Wald χ2-test was reported. All P values were two-sided. Logistic
models adjusting for age and sex of the patients, neo-adjuvant treatment (yes/no) and
cumulative oxaliplatin dose normalized by body surface area (mg m−2), were run. The
potential confounding effect of pre-operative treatment was also tested through a sensitivity
analysis by excluding patients who underwent pre-operative radio- or chemotherapy. The
SAS software (version 9.2) was used for all the analyses.
To control for multiple testing, q-value (a false discovery rate (FDR)-adjusted P value, FDR
0.1) was calculated for each SNP implemented in the R-package.28
During the review process of this paper, a post-hoc power analysis was performed for the
main study endpoint, that is, severe neurotoxicity, using the Genetic Power Calculator
(http://pngu.mgh.harvard.edu/~purcell/gpc/).29 This study has a power of 79.2, 57.8 and
30.2% to detect a genotype relative risk of 1.5 with an alpha-level of 0.05, 0.01 and 0.001,
respectively. The power was evaluated under the assumption of the following parameters:
additive inheritance model, prevalence of severe neurotoxicity phenotype = 0.4 and average
risk allele frequency = 0.30.
Pairwise linkage disequilibrium (LD) analysis for ABCC1 and ABCC2 polymorphisms was




Ten of the 154 patients enrolled into the study were considered ineligible for this
pharmacogenomic analysis according to the study criteria (1 was stage I; 2 were completely
resected stage IV; 1 received 5-fluorouracil alone; 1 received FOLFOX plus bevacizumab, 5
were lost during follow-up), thus leaving 144 eligible patients. The majority of the patients
(56%) completed all the 12 planned cycles of chemotherapy (mean of 10 cycles, range 1–
12). Nineteen patients (13%) underwent neo-adjuvant radiotherapy with or without systemic
chemotherapy (Table 1).
Grade 3–4 toxicity of any type was experienced by 48% of patients (69/144): 18% (26/144)
developed non-hematological grade 3–4 toxicity and 39% (56/144) developed hematological
grade 3–4 toxicity. Neutropenia (38%) was the most common severe hematological toxicity,
whereas diarrhea (11%) and neurotoxicity (7%) were the most frequent non-hematological
severe toxicities. Neurotoxicity was also the most common adverse event of any grade
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developed during the treatment (83%). A detailed description of patient toxicity is in Table
2.
Validation of polymorphisms previously associated with FOLFOX4 toxicity in the
metastatic setting
We included in the analysis 23 genetic polymorphisms previously investigated in metastatic
CRC patients treated with FOLFOX4. Six of them were associated with severe toxicity
(either neurotoxicity or neutropenia) in at least one study. GSTP1-rs947894 and rs1138272,
AGXT-rs4426527, rs34116584 and del-74 bp were associated with neurological toxicity,
whereas GSTM1-null genotype was related to severe neutropenia (Supplementary Table 1).
None of the associations reported in previous studies in the metastatic setting were
replicated in the present study (Table 3).
New discoveries of genetic polymorphisms and neurological toxicity
Neurotoxicity of grade ≥2 was the primary endpoint for this analysis, because of its
prevalence (39%) and clinical relevance (grade 2 indicates moderate motor symptoms and
sensory symptoms extended to ankle and wrist, and grade 3 indicates motor symptoms
requiring help/assistance and sensory symptoms extended to knee and elbow).
Polymorphisms in ABCC1 and ABCC2 were associated with this phenotype (Table 4). The
minor frequency alleles of rs2074087 and rs35587 in ABCC1 were associated with a reduced
risk of neurotoxicity. The minor frequency alleles of rs3740066, rs1885301, rs4148396 and
rs717620 in ABCC2 were associated with an increased risk of neurotoxicity, whereas the
minor frequency allele of rs2273697 was associated with a reduced risk of neurotoxicity.
The minor frequency allele of rs2622604, in ABCG2 was associated with an increased risk
of neurotoxicity. FDR analysis pointed out that five out of eight predictive markers have a q-
value <0.1.
Analysis of LD among the above SNPs identified significant LD among the ABCC2
polymorphisms (Figure 1), but not among the ABCC1 polymorphisms (results not shown).
Therefore, we performed a haplotype analysis on ABCC2 variants to test whether haplotypes
are more predictive than single variants. Haplotype I (16%, all the protective alleles) and II
(19%, all the risk alleles) were selected but no significant association with grade ≥2
neurotoxicity was found (Table 4).
New discoveries of genetic polymorphisms and severe (grade ≥3) toxicity
Grade ≥3 neutropenia was significantly associated to polymorphisms in hMSH6
(rs3136228), ABCC1 (rs35587) and ABCC2 (rs717620). One of them was below the FDR
threshold. Polymorphisms in XRCC3 (rs1799794, rs861539), XRCC1 (rs3213239), APE1
(rs1130409), PARP (rs1136410) and the GSTT1 null genotype were associated with severe
non-hematological toxicity, but only XRCC3-rs1799794 passed the FDR cutoff and was
associated with an increased risk of toxicity (Table 5).
For any of the above associations, the exclusion of 19 pre-treated rectal cancer patients, did
not result in a substantial modification of the statistical meaning of the results (results not
shown).
DISCUSSION
To our knowledge, this is the first study investigating pharmacogenomic markers of toxicity
in a group of CRC patients homogeneously treated with adjuvant FOLFOX4, whereas
several studies have been published in the advanced disease.18,19,26,33 There is a great
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clinical interest in the discovery of predictive biomarkers of treatment outcome and toxicity
in the oncological field and important results have been obtained, especially for the
gastrointestinal disease.1,34
The introduction of FOLFOX4 has led to significant improvements in the clinical outcome
of CRC patients.7,35 FOLFOX4 has an acceptable toxicity profile, with neutropenia and
sensory peripheral neuropathy as the most clinically significant and often dose-limiting
toxicities. Nonetheless, the persistence of neurological toxicity after the interruption of
FOLFOX4 has been recently reported in a high percentage of patients (58–83%).12
Symptoms of neurotoxicity could persist also in patients who experienced grade 2 toxicity
during the course of treatment. Therefore, there is an urgent need to identify predictive
markers of mild-to-severe toxicity in order to avoid long-term disability, especially in
patients with favorable prognosis. In agreement with similar previous studies,7 39% of
patients developed grade 2 or 3 toxicity in our study. This toxicity is common and clinically
relevant, and deserves a thorough investigation of its potential genetic basis. We aimed to
validate previous associations in the metastatic setting, and discover new putative marker for
further investigation.
A comprehensive panel of SNPs was selected to include all the most relevant
polymorphisms previously reported as significant markers of toxicity in FOLFOX4 in
metastatic CRC patients (Supplementary Table 1). In the present study we did not replicate
the predictive role of the GSTP1-rs947894 polymorphism on neurotoxicity previously
reported in advanced CRC patients treated with FOLFOX4.18,19,24,26 The clinical validity of
this marker has been already put into question.25,27,36 Moreover, our study seems to suggest
that its effect (if any) might be context dependent. GSTP1 is an enzyme mediating
glutathione-related detoxification of oxaliplatin. This detoxification pathway might be
dependent upon systemic oxidative stress, which is known to be impaired in patients with
metastatic disease.22
Findings from similar pharmacogenomic studies conducted in different settings should be
interpreted with caution. The biological scenario of patients with early disease treated with
adjuvant oxaliplatin differs from that of patients with metastatic disease. The molecular and
metabolic changes related to tumor metastatization involve several pathways, including the
glycolysis, the tricarboxylic acid cycle, the pentose phosphate pathway, fatty acid and
nucleotide biosynthesis and the GSH-dependent antioxidative pathway.37 Thus, because of
the role played by these pathways in the pathophysiology of oxaliplatin neurotoxicity,12,38 it
is plausible that genetic polymorphisms could have a different impact depending upon the
clinical setting.
The panel of SNPs for genotyping in this study was enriched with SNPs of oxaliplatin
pharmacology, in addition to the variants previously proposed as markers in the metastatic
setting. The main finding of this study is the involvement of trans-cellular transporters, in
particular ABCC2 and ABCC1, in the occurrence of FOLFOX4 toxicity. We identified five
genetic polymorphisms in ABCC2 (rs3740066, rs1885301, rs4148396, rs717620) and
ABCC1 (rs2074087) as predictors of grade 2–3 neurological toxicity, with an FDR <10%,
and therefore considered noteworthy predictive markers. Similar associations were also
obtained for severe neutropenia though they did not pass the 10% FDR cutoff (Table 5).
ABCC1 and ABCC2 belong to ATP-binding cassette transporter superfamily, containing
several family members that mediate the cellular trafficking of drugs, their metabolites and
endogenous factors.39 ABCC1 and ABCC2 may act in a synergistic way modulating the
effect of oxaliplatin and 5-fluorouracil at the cellular level.40
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ABCC2-rs717620, located on the gene promoter region, has been previously associated to
decreased protein expression in vitro,41 and was associated with a 13-fold increased risk of
grade 2–3 neurological toxicity in our study. It was also associated to a five-fold increased
risk of severe neutropenia, though this association had a q-value higher than 0.10 (0.1228)
(Table 5). ABCC2-rs717620 and rs3740066 had a combined effect in increasing platinum-
related toxicity in lung cancer patients,42 similar to our results. In addition to the ABCC2
variants passing the FDR cutoff, ABCC2-rs2273697 was associated with a protective effect
for grade 2–3 neurological toxicity in our study (Table 4). Although this association did not
pass the FDR cutoff (q-value 0.1109), rs2273697 is a missense polymorphism causing a
Val417Ile amino-acid substitution increasing the transporter efficiency.41 Enhanced ABCC2
expression can lead to decreased cellular glutathione content.43 Glutathione is needed for
oxaliplatin detoxification via conjugation, and it was reported that low glutathione intra-
cellular levels can cause increased oxaliplatin cytotoxicity.40 Moreover, ABCC2 mediates
the export of the oxaliplatin-glutathione conjugated form, and ABCC2 overexpressing cells
were resistant to platinum derivatives.44 Taken together with our results, ABCC2 variants
might change the susceptibility of patients to oxaliplatin toxicity via a glutathione-mediated
mechanism.
For ABCC1, three genetic polymorphisms were associated with grade 2–3 neurological
toxicity and one of them was also associated to severe neutropenia. The functional effect of
these variants is not known, and they are not in LD with any known ABCC1 functional
variants. Overexpression of the ABCC1 protein was related to resistance to 5-fluorouracil in
vitro.40 This could be due to the ability of ABCC1 to extrude folates and thus depleting their
intra-cellular availability for the activity of 5-fluorouracil. This might in part explain the
effect of ABCC1-rs35587 on both neutropenia and neurological toxicity, suggesting that
ABCC1-rs35587 might increase the function or expression of the ABCC1 transporter. More
confirmatory studies (both at the clinical and molecular level) should be conducted to
confirm the clinical associations and their mechanistic basis.
XRCC3-rs1799794 was associated with severe non-hematological toxicity (q-value =
0.0235). XRCC3 is a DNA repair protein that is part of the double strand break repair
machinery. Its reduced activity is associated with significantly higher levels of bulky DNA
adducts.45 Our study suggests that this SNP might confer reduced DNA repair of oxaliplatin
DNA adducts, leading to more toxicity. However, the molecular function of this SNP is
presently unknown, and controversial data have been reported on the possible clinical role of
this SNP on the response and toxicity to DNA damaging agents.46,47
hMSH6-rs3136228 was associated with increased risk of severe neutropenia (q-value =
0.0937). hMSH6, expressed in normal marrow cells,48 deals with the DNA mis-match
repair. In particular, it forms an heterodimeric complex with MSH2 able to recognize
mispaired bases in DNA. A functional mis-match repair system is required for the detection
of damaged DNA created by platinum derivatives.49 The rs3136228 polymorphism, seems
to modulate gene transcription causing the loss of a Sp1-binding site.50 It is likely that the
rs3136228 variant can affect mis-match repair activity in non cancer cells modulating the
toxic effects of FOLFOX.
For the novel SNPs indentified in this study, the limited number of patients and lack of an
independent validation cohort make our findings preliminary, requiring further confirmation.
The use of an oxaliplatin-specific scale23 could impair the ability to replicate our findings in
studies using the definitions of the NCI-CTC.51,52 Our study did not validate existing
markers previously identified in metastatic patients, and provides the basis for testing the
validity of new markers in future studies in adjuvant FOLFOX. Among those, the variants in
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ABCC2 have a clinical effect that is consistent with their molecular function, and should be
prioritized for testing of their clinical validity in future studies.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Pairwise linkage disequilibrium analysis among ABCC2 polymorphisms associated to
neurotoxicity grade ≥2. The value within each diamond represents the pairwise correlation
between polymorphims (measured as D’ (a) or r2 (b)). The black to white gradient reflects
higher to lower values. The plots were generated by HaploView 3.32.30
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Table 1




 Male 82 (56.9)
 Female 62 (43.0)
Age (Mean, range) 59 (25–82)
Primary tumor site
 Colon 111 (77)
    Right 39 (35)
    Left 68 (61)
    Transverse 3 (3)
    Sigma 1 (1)
 Rectum 33 (23)
Stage of disease at diagnosis a
 II 21 (15)
 III 123 (85)
Neo-adjuvant radiotherapy (only for rectum)
 Yes 19 (58)
 No 14 (42)
Neo-adjuvant chemotherapy (only for rectum)
 5-FU 10 (30)
 5-FU—FA and oxaliplatin 3 (9)
Number of cycles (Mean, range) 10.4 (1–12)
Patients who received all 12 planned cycles 81 (56)
Total (mg) oxaliplatin dose
 Median (range) 1460 (145–2166)
 Dose per m2 (mg m−2): median (range) 886 (85–1020)
 Dose per m2 per week: median (range) 35 (17–54)
a
TNM scale.
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Table 2









 Diarrhea 53 36.8 16 11.1
 Nausea 68 47.2 3 2.1
 Vomiting 30 20.8 4 2.8
 Asthenia 44 30.5 0 0
 Alopecia 19 13.2 0 0
 Mucositis 32 22.2 2 1.4
 Hepatic
 (hyperbilirubinemia)
6 4.2 1 0.7
 Infection without
 severe neutropenia
9 6.2 0 0
 Neurotoxicityb 120 83.3 10 6.9
Hematological toxic effects
 Anemia 64 44.4 0 0
 Neutropenia 91 63.2 54 37.5
 Leukopenia 54 37.5 8 5.5
 Fever with severe
 neutropenia
4 2.8 2 1.4
 Thrombocytopenia 59 41.0 1 0.7
a
According to the NCI-CTC version 3.
b
According to the oxaliplatin-specific scale (23).
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Table 3
Associations between genetic polymorphisms previously related to toxicity in FOLFOX4 metastatic CRC
SNP Gene Base change MAF Most significant genetic model
Grade ≥2 toxicity Grade 0–1 toxicity Model OR (95% CI) Pa
Neurological toxicity
rs947894 GSTP1 A>G 0.321 0.301 Dominant 1.16 (0.59–2.30) 0.6647
rs1138272 GSTP1 C>T 0.071 0.080 Additive 0.91 (0.35–2.38) 0.8433
rs4426527 AGXT A>G 0.241 0.247 Additive 0.93 (0.52–1.65) 0.7946
rs34116584 AGXT C>T 0.277 0.227 Additive 1.29 (0.73–2.27) 0.3863








deletion 0.192 0.237 Additive 0.73 (0.41–1.32) 0.2995
Abbreviations: CI, confidence interval; MAF, minor allele frequency; OR, odds ratio; SNP, single-nucleotide polymorphism.
a
Adjusted for sex, age, neo-adjuvant therapy and oxaliplatin cumulative dose normalized by BSA (for neurological toxicity).
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Table 4
Significant associations between genetic polymorphisms and grade ≥2 neurological toxicity. Associations with
q<0.10 are in bold
SNP Gene Base
change





Model OR (95% CI) Pa q**
rs2074087 ABCC1 G>C 0.0750 0.2529 Additive 0.43 (0.22–0.86) 0.0170 0.0881
rs35587 ABCC1 T>C 0.2455 0.3000 Dominant 0.47 (0.23–0.96) 0.0375 0.1049
rs1885301 ABCC2 G>A 0.5982 0.4419 Recessive 3.06 (1.35–6.92) 0.0072 0.0747
rs717620 ABCC2 C>T 0.2455 0.1782 Recessive 14.39 (1.63–127.02) 0.0164 0.0881
rs2273697 ABCC2 G>A 0.1340 0.2300 Dominant 0.44 (0.20–0.98) 0.0434 0.1049
rs4148396 ABCC2 C>T 0.4629 0.3512 Recessive 4.69 (1.60–13.74) 0.0048 0.0747
rs3740066 ABCC2 C>T 0.4545 0.3353 Recessive 2.99 (1.16–7.70) 0.0231 0.0958
rs2622604 ABCG2 C>T 0.3092 0.2118 Recessive 3.61 (1.01–12.88) 0.0478 0.1049
ABCC2
haplotype
rs1885301 rs717620 rs2273697 rs4148396 rs3740066 Model OR (95% CI) P q**
(I)
(Protective)
G C A C C Additive 0.60 (0.30–1.16) 0.1296 —
(II) (Risk) A T G T T Additive 1.72 (0.95–3.09) 0.0722 —




Adjusted for sex, age, neo-adjuvant therapy and oxaliplatin cumulative dose normalized by BSA.
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Table 5
Significant associations between genetic polymorphisms and grade 3–4 toxicity. Associations with q<0.10 are
in bold
SNP Gene Base change MAF Most significant genetic model
Grade ≥3 toxicity Grade 0–2 toxicity Model OR (95% CI) Pa q**
Neutropenia
 rs3136228 hMSH6 T>G 0.509 0.410 Recessive 3.23 (1.38–7.57) 0.0071 0.0937
 rs35587 ABCC1 T>C 0.204 0.325 Additive 0.54 (0.31–0.96) 0.0368 0.1273
 rs717620 ABCC2 C>T 0.269 0.165 Additive 1.81 (1.01–3.26) 0.0466 0.1273
Any non-hematological toxicity
 rs1799794 XRCC3 A>G 0.365 0.225 Recessive 8.90 (2.48–31.97) 0.0008 0.0150
 rs861539 XRCC3 C>T 0.2917 0.4435 Additive 0.49 (0.24–1.00) 0.0495 0.1326
 rs3213239 XRCC1 InDel 0.212 0.406 Additive 0.39 (0.19–0.82) 0.0130 0.1217
 rs1130409 APE 1 T>G 0.6042 0.4396 Additive 1.99 (1.05–3.74) 0.0339 0.1326
 rs1136410 PARP T>C 0.2500 0.1710 Dominant 2.77 (1.07–7.21) 0.0366 0.1326
 N/A GSTT1 Gene deletion 0.500 0.364 Recessive 2.82 (1.02–7.83) 0.0467 0.1326




Adjusted for sex, age, neo-adjuvant therapy.
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